Investors are keenly awaiting further signals of easing tensions between President Donald Trump and his counterpart Xi Jinping, with the upcoming May 14-15 summit viewed as a crucial juncture to potentially remove a significant overhang on Chinese markets. Geopolitical and trade issues remain firmly in focus as market participants assess the implications for regional equities and the broader economic outlook.
While expectations for a concrete, comprehensive deal between the world’s two largest economies remain subdued, analysts suggest that the meeting of the two leaders could nonetheless serve to calm prevailing trade tensions. Any such improvement, coupled with a prospective easing of curbs on US technology exports to China, holds the potential to significantly boost Chinese exporters and tech hardware manufacturers. This sentiment is particularly relevant given that Chinese equities have recently lagged their Asian peers, even as regional markets experienced a rally last month on the back of easing concerns surrounding the Iran conflict. Furthermore, optimism for a stronger yuan is reportedly building amidst a retreat in the dollar.
However, the stakes are high. Any structural disagreements emerging from the summit could swiftly reignite volatility across local stocks, underscoring the delicate balance of the US-China relationship. Christopher Hamilton, head of client solutions for Asia Pacific ex-Japan at Invesco Ltd., emphasized this point, stating, “If the summit can bring a little bit more certainty to the US-China relationship and drive that risk premium down, that’s ultimately going to be very positive for Chinese equities.”
Trade Tariffs: A Persistent Headwind
A primary area of scrutiny for market participants revolves around trade tariffs. According to Macquarie Group Ltd., the base case scenario anticipates tariffs remaining in place without a meaningful escalation. Current US levies on Chinese goods are estimated by JPMorgan Chase & Co. to be at an effective rate of approximately 22%. These tariffs are subject to ongoing investigations, which China has consistently cited as a source of friction in bilateral relations.
Eugene Hsiao, head of China equity strategy at Macquarie in Hong Kong, noted that “An absence of further tensions marginally improves visibility for broader China exporters by easing escalation risk and providing better supply-chain certainty, even as existing tariffs continue to cap upside.” While companies involved in energy security or the global tech supply chain may be more likely to secure waivers, higher levies present a particularly challenging environment for biotech firms with substantial US revenue exposure. Companies such as WuXi Biologics (Cayman) Inc. and WuXi AppTec Co. are already facing pressure due to the Biosecure Act, making the tariff situation even more critical for their outlook.
Geopolitical Strain: The Iran Factor
Adding another complex layer to the US-China relationship is the ongoing Middle East conflict, specifically the Iran war. Washington’s intensified efforts to exert pressure on Tehran are increasingly impacting China, which stands as Iran’s largest trading partner and a major consumer of its oil exports. The US has already imposed sanctions on refiners in the Asian country that process Iranian oil, further complicating the geopolitical landscape.
President Trump has publicly stated his intention to discuss the Iran war with President Xi during their summit. A clear signal of easing tensions on this front could significantly improve overall risk sentiment, given that previous meetings between the two leaders have frequently triggered sharp swings in global shares. The interconnectedness of trade, technology, and geopolitical stability means that any outcome from the May 14-15 discussions will be closely dissected by investors seeking clarity and direction in an uncertain market environment.
